Dorez (bisoprolol) coated tablets 2.5 mg. №30


Manufacturer: Macedonia

Arterial hypertension; coronary heart disease (angina); chronic heart failure with left ventricular systolic dysfunction in combination with ACE inhibitors, diuretics, and, if necessary, cardiac glycosides.

Out of stock



Dorez Storage
active substance: bisoprolol (bisoprolol);

1 film-coated tablet contains bisoprolol fumarate 2.5 mg;

Dorez excipients: siliconized microcrystalline cellulose (microcrystalline cellulose 98% / colloidal anhydrous silica 2%); crospovidone; glycerol dibegenate;

shell: white white Y-1-7000 (hypromellose, macrogol 400, titanium dioxide (E 171)).

Dorez Dosage form
Film-coated tablets.

Main physical and chemical properties: round biconvex, film-coated white tablets, with a line on one side.

Pharmacotherapeutic group
Selective beta-blockers.

ATX code C07A B07.

Pharmacological properties


Bisoprolol is a potent selective beta1-blocker, without its own sympathomimetic activity, has no membrane-stabilizing effect.

The mechanism of its antihypertensive action is unclear, but it is known that bisoprolol significantly reduces the level of renin in blood plasma.

In patients with angina, blockade of beta1-receptors leads to a decrease in cardiac activity and, consequently, to a decrease in myocardial oxygen demand. Effective in the treatment of stable chronic moderate and severe heart failure with reduced ventricular systolic function.


Bisoprolol is almost completely absorbed from the gastrointestinal tract. Due to the slight metabolism during the first passage through the liver, it can be concluded that bisoprolol has a high bioavailability. Eating does not affect the absorption of bisoprolol.

There are no active metabolites.

The drug is excreted equally through the liver and kidneys. The half-life from blood plasma (10-12 hours) provides efficiency within 24 hours after reception 1 time a day.

Chronic heart failure with left ventricular systolic dysfunction in combination with ACE inhibitors, diuretics, and, if necessary, cardiac glycosides.

Acute heart failure or heart failure in the stage of decompensation, requiring intravenous ionotropic therapy;
cardiogenic shock;
atrioventricular block II and III degree (except for that in patients with an artificial pacemaker);
sinus node weakness syndrome;
sinoatrial block;
symptomatic bradycardia;
symptomatic hypotension;
severe asthma;
late stages of peripheral circulatory disorders or Raynaud’s disease;
untreated pheochromocytoma;
metabolic acidosis;
hypersensitivity to bisoprolol or to other components of the drug.
Interaction with other medicinal products and other forms of interaction
Combinations not recommended.

Calcium antagonists of the verapamil group and to a lesser extent diltiazem: adverse effects on myocardial contractility and AV conduction. Intravenous administration of verapamil to patients on beta-blocker therapy may lead to severe hypotension and AV blockade.

Class I antiarrhythmics (eg quinidine, disopyramide, lidocaine, phenytoin, flecainide, propafenone): possible potentiation of the effect on atrioventricular conduction and enhancement of the negative inotropic effect.

Centrally acting antihypertensive drugs (eg, clonidine, methyldopa, moxonidine, rilmenidine): lead to progression of heart failure due to decreased central sympathetic tone (decreased heart rate, cardiac output, vasodilation). Abrupt discontinuation of the drug, especially if previously stopped taking beta-blockers, can lead to rebound hypertension.